Bank of China Group Investment ^Investors

A consortium of Chinese investment firms have acquired stake in SciClone, a California Pharmaceutical firm, for $605 million.. Headquartered in Foster City California and listed on NASDAQ, SciClone is a revenue-generating pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders.